The Price War On Drugs: HCV Competition Finally Sparks Discounting
Executive Summary
The approval of Abbvie’s Viekira Pak combination HCV therapy has touched off a round of discounting in the high-profile specialty drug arena that is likely to bleed into other existing and future competitive markets.
You may also be interested in...
Pharma CEOs Tackle A Tough Question: “Why Don’t People Like You?”
Pfizer CEO Ian Read, Regeneron CEO Leonard Schleifer, Gilead CEO John Milligan and Lilly’s incoming CEO David Ricks discussed pharma’s reputation problem during the Forbes Healthcare Summit.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.